On January 16, 2020 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, reported that an abstract on new Phase 1 translational results for BPX-601, its lead GoCAR-T product candidate, has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI) (Press release, Bellicum Pharmaceuticals, JAN 16, 2020, View Source [SID1234553311]). The meeting is being held January 23-25, 2020 in San Francisco.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Title: Tumor Infiltration and Cytokine Biomarkers of Prostate Stem Cell Antigen (PSCA)-Directed GoCAR-T Cells in Patients with Advanced Pancreatic Tumors
Poster Board: M1, Abstract 734
Presenter: Joanne Shaw, Ph.D.
Time/Location: Friday, January 24, 2020, 12 p.m. to 1:30 p.m., 4:30 p.m. to 5:30 p.m. PT, Level 1, West Hall